Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 17/20 | 1.00 |
| ▸ | EDNRB | P24530 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230639 | 0.86 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL7857330 | 0.86 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL7858648 | 0.83 | EDNRA (0.70) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7856711 | 0.81 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7849834 | 0.81 | EDNRA (0.78) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7857530 | 0.81 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7860467 | 0.81 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL23467 | 0.81 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL788644 | 0.81 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7716850 | 0.81 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20060178400-A1 | Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LABORATORIES | 2006-08-10 | — | — | US | disclosed |
| EP-1069114-A2 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | EDNRA 802/4885EDNRB 1113/4885MEN1 2828/4885 |
| US-20060178400-A1 | Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ACACA, ACACB, ACAT1 | EDNRA 1888/4885EDNRB 1821/4885MEN1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.